Ask AI
ProCE Banner Activity

INAVO120: Evaluating PIK3CA Mutation Assays of Blood and Tissue From Phase III Trial of Palbociclib and Fulvestrant ± Inavolisib for Hormone Receptor–Positive/HER2-Negative ABC

Conference Coverage
Slideset

Using samples from screened and enrolled participants in the phase III INAVO120 trial, analysis shows that both blood-based and tissue-based PCR and NGS platforms reliably detect PIK3CA mutations to identify patients with hormone receptor–positive/HER2-negatvie advanced breast cancer eligible for inavolisib treatment.

Released: December 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer